Cargando…
Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients
Oral bioavailability of paclitaxel is very low, which is due to efficient transport of the drug by the intestinal drug efflux pump P-glycoprotein (P-gp). We have recently demonstrated that the oral bioavailability of paclitaxel can be increased at least 7-fold by co-administration of the P-gp blocke...
Autores principales: | Malingré, M M, Beijnen, J H, Rosing, H, Koopman, F J, Jewell, R C, Paul, E M, Huinink, W W Ten Bokkel, Schellens, J H M |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2001
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363627/ https://www.ncbi.nlm.nih.gov/pubmed/11139311 http://dx.doi.org/10.1054/bjoc.2000.1543 |
Ejemplares similares
-
The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients
por: Malingré, M M, et al.
Publicado: (2001) -
Oral topotecan: bioavailability and effect of food co-administration
por: Herben, V M M, et al.
Publicado: (1999) -
The acridonecarboxamide GF120918 potently reverses P-glycoprotein-mediated resistance in human sarcoma MES-Dx5 cells
por: Traunecker, H C L, et al.
Publicado: (1999) -
Phase II trial of topically applied miltefosine solution in patients with skin-metastasized breast cancer
por: Terwogt, J M M, et al.
Publicado: (1999) -
Inhibitory effect of the reversal agents V-104, GF120918 and Pluronic L61 on MDR1 Pgp-, MRP1- and MRP2-mediated transport
por: Evers, R, et al.
Publicado: (2000)